1259007-23-2

Upstream product

• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 1338831-07-4 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetic acid 
• 89-62-3 4-methyl-2-nitroaniline 
• 1338831-06-3 ethyl 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetate 
• 1259007-33-4 5-chloro-1-(2,4-dichlorophenyl)-1H-1,2,4-triazole 
• 106103-85-9 2-(2-(2,4-dichlorophenyl)hydrazono)acetic acid 

Relevant academic research and scientific papers

Arylazolylthioacetanilide. Part 8*: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3- ylthio)-N-arylacetamides As Potent HIV-1 inhibitors

The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency. Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamide derivatives were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral analysis, evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT. The results showed that some of the new compounds displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs. However, all newly synthesized derivatives were not active against HIV-2 replication.